Depressive disorders in epilepsy …

Epilepsy & Seizures

Updated 05.10.2023
Released 09.16.2014
Expires For CME 05.10.2026

Depressive disorders in epilepsy

Authors: Maria Raquel Lopez MD, Andres M Kanner MD

See Contributor Disclosures

Editor: Jerome Engel Jr MD PhD

Depressive disorders in epilepsy

In This Article

Quick Link

Introduction

Overview

Mood and anxiety disorders are the most common psychiatric comorbidities in patients with epilepsy. The prevalence rates of mood disorders have varied widely in the literature based on diversity in methodologies and sample populations across studies. Major depressive episodes are the most frequently identified mood disorders. In a meta-analysis by Fiest and colleagues, the prevalence was 23.1%; it was 22.9% and 21.9% in two subsequent meta-analyses (33; 106). Mood disorders are more common in females with and without epilepsy (38).

Its prevalence has been underestimated due to the underreporting of depressive episodes by patients and families and under-recognition by clinicians, starting with the failure of neurologists to investigate the existence of these common comorbidities during the initial evaluation or even throughout the course of treatment (62; 104). Several studies have established a higher prevalence of depressive disorders in patients with epilepsy than in healthy controls (80; 14) and people with chronic medical disorders (53; 113). Furthermore, population-based studies have established the existence of a bidirectional relationship between epilepsy and depression (49; 47; 46; 57).

There is an ongoing debate as to whether depression in patients with epilepsy differs from that in people with primary mood disorders (58). Proponents of both schools of thought are probably correct as a significant percentage of patients can experience any of the various forms of primary mood disorders, including major depressive disorder, dysthymic disorder, bipolar disorder, and cyclothymic disorder indistinguishable from those described in the Diagnostic and Statistical Manual of Mental Disorder (DSM), fifth edition (04). By the same token, several authors have identified atypical clinical manifestations of mood disorders that fail to meet any of the diagnostic criteria suggested in the various editions of the DSM in a significant proportion of patients with epilepsy (97; 64; 27). Kraepelin and Bleuler were the first to recognize a “unique” clinical presentation of mood disorders consisting of recurrent episodes of “dysphoric symptoms” in patients with epilepsy (87). Gastaut expanded on Kraepelin’s initial observations, and Blumer coined the term “interictal dysphoric disorder” (12; 89).

The purpose of this article is to provide a comprehensive review of mood disorders in adults with epilepsy, with special attention to epidemiologic and clinical data; the underlying pathogenic mechanisms, including common pathogenic mechanisms that may be operant in depression and epilepsy; and the basic principles of their treatment.

Key points

	• Depressive disorders are the most frequent psychiatric comorbidity in patients with epilepsy.
	• Depression in patients with epilepsy can present with atypical clinical manifestations that fail to meet diagnostic criteria included in the Diagnostic and Statistical Manual of Mental Disorders.
	• Depressive disorders are likely to worsen the quality of life of patients with epilepsy, increase the suicidal risk of patients, worsen their tolerance of antiepileptic drugs, and increase the economic burden on their family and society.
	• Patients with epilepsy and a comorbid depression are more likely to suffer from treatment-resistant epilepsy, and patients with temporal lobe epilepsy undergoing epilepsy surgery are less likely to achieve full remission of auras following epilepsy surgery.
	• A bidirectional relationship exists between depressive disorders and epilepsy. The scientific evidence supports the expression of the existence of common pathogenic mechanisms operant in both disorders and explains why patients with depression have a 2- to 5-fold higher risk of developing epilepsy and more than 20% of patients with epilepsy suffer from depression (59).
	• The treatment modalities used in the management of primary depressive disorders can be applied to the management of patients with epilepsy.

Historical note and terminology

The close and complex relationship between depressive disorders and epilepsy has been recognized for 26 centuries, when Hippocrates wrote: “melancholics become epileptics and epileptics melancholics.” In that statement, Hippocrates suggested the existence of a bidirectional relationship between the two disorders whereby “having depression increases the risk of developing epilepsy and vice-versa.” This observation was confirmed in population-based studies performed in last 30 years. The advent of modern psychiatry recognized the clinical similarities between depressive disorders of patients with epilepsy and primary depressive disorders. Yet, in 1923 Kraepelin suggested that depressive disorders in patients with epilepsy could also have a pleomorphic presentation that included symptoms of depression, anxiety, irritability, and pain as well as hypomanic symptoms, all of which increased in severity during the peri-ictal period (eg, preceding or following a seizure). These observations were confirmed by Bleuler in the 1940s and Gastaut 10 years later. Blumer coined the term of “interictal dysphoric disorder of epilepsy” to describe this form of depression in patients with epilepsy (11). Other authors have suggested that this form of depression is not specific to patients with epilepsy, as it has been identified in patients with migraine (88).

Clinical manifestations

Presentation and course

Depressive disorders in patients with epilepsy may be identical to primary depressive disorders. Nonetheless, in approximately 30% to 50% of these patients, depressive episodes can present with atypical clinical manifestations and fail to meet the diagnostic criteria included in the Diagnostic and Statistical Manual of Mental Disorders-V (04). They consist of symptoms of depression intermixed with brief euphoric moods, irritability, anxiety, paranoid feelings, and somatoform symptoms (anergia, atypical pain, and insomnia). They tend to follow a chronic course with recurrent symptom-free periods.

More often than not, depressive and anxiety disorders occur together. For example, in a study of 188 consecutive patients with epilepsy, 31 met DSM-IV criteria of a current major depressive episode. Twenty-one of these patients had a mixed major depressive episode and an anxiety disorder (64). Recognition of such comorbidity is of the essence as failure to include it in the treatment plan can result in recurrence of the depressive disorder. In addition, comorbid depressive and anxiety disorders in patients with and without epilepsy are associated with a worse course of the depressive disorder and a worse quality of life compared to that of patients with only a depressive disorder.

Often, depressive disorders can be associated with personality disorders. In such cases, the response to treatment is poor and the overall prognosis is worse. Of note, personality disorders are rarely recognized in the evaluation of patients with epilepsy, and their prevalence is yet to be investigated in population-based studies. Most of the data available are derived from case series from tertiary centers (74).

Clinical manifestations particular to epilepsy

The occurrence of psychiatric symptoms in patients with epilepsy can be temporally related to that of seizures, either preceding it (preictal), following it (postictal), as an expression of the seizure (ictal), and independent of the of the seizure (interictal). In general, interictal depressive disorders are the ones more frequently identified whereas peri-ictal expressions often go unrecognized.

Preictal symptoms of depression. Preictal symptoms of depression typically present as a dysphoric mood in which the symptoms may extend for hours or even 1 to 3 days prior to the onset of a seizure. For example, Blanchet and Frommer assessed mood changes over a period of 56 days in 27 patients with epilepsy who rated their mood on a daily basis (10). Mood ratings pointed to a dysphoric state 3 days prior to a seizure in 22 patients (81%). This change in mood was greatest during the 24 hours preceding the seizure. Patients or parents of children with epilepsy often report that dysphoric symptoms completely resolve the day after the ictus.

Postictal symptoms of depression. Postictal symptoms of depression have been recognized for decades but have been investigated in only a few studies. The largest study that investigated the prevalence of postictal psychiatric symptoms in a systematic manner included 100 consecutive patients with treatment-resistant focal epilepsy (69). Postictal symptoms of depression were identified in 43 of 100 consecutive patients with refractory partial seizure disorders. These symptoms occurred after more than 50% of seizures during the previous 3 months and their duration ranged from 0.5 to 108 hours, with a median duration of 24 hours. These symptoms could occur within 72 hours of the last seizure, and typically a symptom-free period of 12 to 24 hours between the seizure and the onset of the psychiatric symptoms was recorded. Furthermore, postictal suicidal ideation was identified in 13% of patients, and the median duration of these symptoms was also 24 hours. Other studies have suggested that postictal symptoms of depression can outlast the ictus for up to 2 weeks and, at times, have led patients to suicide (43).

Of note, patients with epilepsy may experience interictal depressive episodes with postictal exacerbation in severity of these symptoms (69). Furthermore, in patients with interictal depressive episodes in remission, postictal symptoms of depression can occur despite the presence of adequate doses of antidepressant medication (Kanner unpublished data). This observation suggests a different pathogenic mechanism operant in postictal and interictal depressive symptoms.

Ictal symptoms of depression. Ictal symptoms of depression are the clinical expression of a focal aware seizure in which the depressive symptoms are the sole (or predominant) semiology. Ictal symptoms of depression ranked second after symptoms of anxiety or fear as the most common type of ictal affect in one study (115). This presentation occurred in 21% of 100 patients with epilepsy who reported auras consisting of psychiatric symptoms (22). Yet, the actual prevalence of ictal symptoms of depression is yet to be established in larger studies. The most frequent symptoms include feelings of anhedonia, guilt, and suicidal ideation. Such mood changes are typically brief, stereotypical, occur out of context, and are associated with other ictal phenomena. More typically, however, ictal symptoms of depression are followed by an alteration of consciousness as the ictus evolves from a focal aware to a focal unaware seizure.

Depressive episodes as an iatrogenic effect

Caused by antiepileptic drugs. All antiepileptic drugs can potentially cause psychiatric symptoms, particularly when used at high doses (61). However, antiepileptic drugs with GABAergic properties, primarily phenobarbital, primidone, the benzodiazepines, tiagabine, and vigabatrin are more likely to cause depression (32; 15; 05; 103). Other antiepileptic drugs that have been associated with the development of symptoms of depression include felbamate, topiramate, levetiracetam, zonisamide, and, among the third-generation antiepileptic drugs, perampanel (83; 67; 91; 57; 68). The effects of depression using lacosamide, a third-generation antiepileptic drug, has been evaluated in several studies. Moseley and colleagues examined the NDDI-E and GAD-7 scores prior and following lacosamide treatment and showed no significant effects in the GAD-7 scores and significant improvements in the NDDI-E scores, suggesting that lacosamide is safe to use in patients with mood disorders (86).

Psychiatric adverse events are more likely to be identified in patients susceptible to develop psychiatric disorders, such as those with a past psychiatric history or with a family psychiatric history (91; 57; 68). Accordingly, obtaining personal lifetime and family psychiatric histories is of the essence in identifying patients who may be at risk of developing iatrogenic depressive episodes.

The addition of antiepileptic drugs with mood stabilizing properties, such as carbamazepine, oxcarbazepine, valproic acid, and lamotrigine can very rarely cause depressive episodes. On the other hand, these antiepileptic drugs are associated with the occurrence of depression following their discontinuation in patients with a prior history of depressive disorders that had been kept in remission by these antiepileptic drugs (72).

In 2008, the Food and Drug Administration instructed all manufacturers of antiepileptic drugs to add a warning to their labeling indicating that use of these drugs increases risk for suicidal thoughts and behavior (06). The announcement was based on an FDA meta-analysis of 199 clinical multicenter-randomized, double-blind placebo controlled and parallel trials of 11 antiepileptic drugs. The FDA concluded that patients randomized to antiepileptic drugs had twice the risk for suicidal ideation and behavior than those randomized to placebo (0.43% vs. 0.24%). The FDA data were carefully reviewed by a task force of the American Epilepsy Society, which identified several methodological flaws including: (1) grouping all antiepileptic drugs (which have different mechanisms of action) into one class, and (2) basing the recommendation on spontaneously reported adverse events rather than on systematically acquired data (50). Furthermore, attempts to replicate the data from the FDA meta-analysis in five large studies yielded contradictory findings. Thus, certain but not all antiepileptic drugs can cause psychiatric adverse events that can lead to suicidal ideation and behavior, but this is likely to occur in patients with a predisposition for psychiatric illness. Accordingly, before starting an antiepileptic drug like topiramate, zonisamide, perampanel, vigabatrin, barbiturates, or levetiracetam, it is essential to inquire about a prior personal or family psychiatric history, both of which are clear risk factors for the development of depressive disorders.

Depression following epilepsy surgery. There have been an increasing number of reports of depressive disorders following an anterotemporal lobectomy during the first 3 to 6 months after surgical resection (63; 116). Furthermore, it is not unusual to see “mood lability” within the initial 6 weeks after surgery. Often these depressive disorders subside by 6 to 12 months after surgery. The severity of postsurgical depressive disorders varies from mild to very severe, including suicidal attempts. In most instances, these depressive disorders respond readily to pharmacologic treatment with antidepressant drugs. Patients with a prior history of depression are at greater risk. A German study found that patients with personality disorders are at higher risk of suffering from postoperative psychiatric complications, including psychotic episodes, as compared with patients with other preoperative psychiatric conditions (such as depression) or with patients with no preoperative psychiatric diagnosis whatsoever (74). Although some studies have not found a relationship between depression with the postsurgical control of seizures, others have (96; 63). All patients undergoing epilepsy surgery, therefore, should be advised of this potential complication prior to surgery.

Prognosis and complications

Impact on mortality risk. A population-based study from Sweden found that premature mortality is 11-fold higher in patients with epilepsy than controls (29). Close to 16% of all deaths were attributed to external causes, which included death by suicide and accidents (in a motor vehicle, drug poisoning, falls, drowning, assault, other). In fact, patients with epilepsy had a greater than 3-fold higher risk of premature death from these causes than the control groups. Furthermore, among patients with epilepsy who died from external causes, comorbid psychiatric disorders were identified in 75.2%, the majority of which included depression and substance misuse. It is worth noting that the lifetime prevalence of psychiatric disorders in patients with epilepsy was 40.7%, compared to 10.3% in controls. In a separate population-based study conducted in Denmark, the presence of mood disorders increased the risk of suicide by 32-fold (17). In a review of 21 studies, suicide accounted for 12% of all deaths in patients with epilepsy (55).

Impact on the management of the seizure disorder.

Worse tolerance of antiepileptic drugs. Two studies published in 2011 showed that patients with epilepsy with major depressive episodes endorsed more severe adverse events of antiepileptic drugs (60). The study by Kanner and colleagues demonstrated that the worse tolerance was not limited to major depressive episode but was of comparable magnitude in patients with less severe forms of depression, such as sub-syndromic depressive episodes. Tolerance was worse among patients with epilepsy who experienced comorbid major depressive episodes and anxiety disorders (60).

Worse response to the pharmacologic and surgical treatment of the seizure disorder. Three studies have suggested a worse response of the seizure disorder to pharmacotherapy with antiepileptic drugs. For example, in a study of 780 consecutive patients with new-onset epilepsy followed for a median 79-month period, those with a psychiatric history, particularly depressive disorders, preceding the onset of epilepsy were 2-fold more likely to develop treatment-resistant epilepsy than those without (51). In a separate study of 138 consecutive patients with new-onset epilepsy, those who endorsed symptoms of depression and anxiety before the start of antiepileptic therapy were significantly less likely to be seizure free after 12 months of therapy (95). In another population-based study, patients with a history of depression before the onset of epilepsy and who required pharmacologic treatment and psychotherapy were less likely to be seizure free (57).

Likewise, a lifetime history of psychiatric disorders and depression has been associated with an increased likelihood of persistence of auras or even focal unaware and focal to bilateral tonic-clonic seizures following an anterotemporal lobectomy. For example, in a study of 100 consecutive patients, only 12% of patients who reached complete seizure freedom after surgery (mean follow-up period 8.3±3.3 years) had a lifetime history of depression, whereas such history was identified in 67% of patients who had focal aware, but no focal unaware or focal to bilateral tonic-clonic, seizures and in 79% of patients with persistent disabling seizures (66). These data were confirmed in two other studies that included patients with mesial temporal sclerosis: in one study of 280 patients, those with a preoperative psychiatric diagnosis (38% of the entire cohort) were significantly less likely to remain seizure free (OR 0.53, 95% CI 0.28-0.98, p = 0.04) (18), whereas in the second study of 115 patients, a pre-surgical history of major depressive disorders was a risk factor for persistent postsurgical seizures (OR=5.23; p=0.003) (23). In the largest study from a German epilepsy center, persistence of seizures following an anterotemporal lobectomy was identified in patients with epilepsy and a history of depression, and the likelihood of seizure freedom was even worse among patients with depression and a personality disorder (75). Other studies have questioned the findings of these studies (01); hence, there is still equipoise with respect to this question.

Impact on the quality of life. Several studies of patients with treatment-resistant epilepsy demonstrated that depressive disorders are the most powerful predictor of poor quality of life, even after controlling for seizure frequency, severity, and other psychosocial variables (94; 39; 78; 20; 64). In one of these studies, depression was significantly associated with poor quality-of-life independently of seizure type, but seizure freedom for the previous 3 months improved the quality-of-life ratings (20). Of note, comorbid depressive and anxiety disorders have a worse impact on the quality of life of patients with epilepsy than the depressive or anxiety disorders occurring alone and particularly when a major depressive episode is comorbid with more than one anxiety disorder (64).

Impact on health care costs. Patients with untreated depression were found to use significantly more health resources of all types, independent of seizure type or duration (21). Mild-to-moderate depression was associated with a 2-fold increase in medical visits compared with nondepressed controls whereas severe depression was associated with a 4-fold increase. The presence and severity of depression was a predictor of disability scores, irrespective of the duration of the seizure disorder. Also, depressive disorders have been found to worsen the tolerance of antiepileptic drugs.

Clinical vignette

A 30-year-old female with history of focal epilepsy presented with new symptoms of depression. The patient started having focal seizures with loss of awareness at the age of 20 years. Previous workup revealed a focal epilepsy of left temporal lobe origin of undetermined cause. She was seizure free on lamotrigine monotherapy for the past 10 years. She was diagnosed with tuberculosis 2 months prior to presentation, requiring treatment with isoniazid, rifampin, pyrazinamide, and ethambutol. Her past medical history was significant for a previous episode of depression at the age of 18 years. Her family history was significant for depressive disorders and anxiety disorders in her mother and sister.

She had been seizure free for 2 years, but 1 month prior to presentation she had four focal unaware seizures, all within a 48-hour period for which she was taken to the nearest emergency room where levetiracetam was added to her antiepileptic regimen. In the 2 weeks prior to presentation, she started having symptoms of decreased energy, anhedonia, constant crying, irritability, and overall sadness. She also reported feeling life is not worth living anymore although denied an active suicidal ideation.

This case illustrates iatrogenic depressive episodes caused by two possible mechanisms: (1) the introduction of levetiracetam in a patient who is known to be at risk of iatrogenic effects because of a past history of depressive disorder and positive family history of mood and anxiety disorder and (2) the pharmacokinetic interaction between lamotrigine and rifampin, which resulted in increased clearance of lamotrigine and, in turn, may have unmasked a depressive disorder that was kept in remission by the antidepressant and mood-stabilizing properties of this antiepileptic drug.

The patient had a routine EEG that showed slowing and interictal epileptiform activity over the left temporal region but was basically unchanged when compared to previous studies. A lamotrigine level of 4.5 mcg/mL was lower than a level (8 mcg/ml) obtained one year earlier. The dose was increased to achieve previous serum concentration, blood levels were monitored while she was on rifampin therapy, and levetiracetam was discontinued. Her depression as well as seizures remitted.

Biological basis

Etiology and pathogenesis

The causes of depressive disorders in patients with epilepsy are multiple and more often than not are the result of the interaction of several variables that include the following: (1) a recurrence of a mood disorder that may have preceded the onset of epilepsy; (2) a genetic predisposition for mood disorders; (3) neurobiologic factors associated with the seizure disorder, which are similar to those of primary mood disorders and include changes in neurotransmitters in the central nervous systems, as well as hormonal and inflammatory abnormalities; (4) iatrogenic factors; and (5) psychosocial factors that include adjustment to the obstacles associated with a life with seizures (eg, loss of independence, stigma, need to change work, etc.).

In the past, depressive disorders were considered a “complication” of epilepsy. Yet, data from population-based studies have revealed a more complex relationship--a bidirectional relation between the two disorders, whereby not only are people with epilepsy at greater risk of developing depressive disorders, but people with primary depressive disorders are at greater risk of developing epilepsy. For example, in one study, Hesdorffer and colleagues used the United Kingdom’s General Practice Research Database to compare the incidence ratio of primary psychiatric disorders (eg, depression, anxiety, suicidality, and psychosis) during the 3 years that preceded and followed the onset of the seizure disorder between 3773 patients with epilepsy and 14,025 controls 10 to 60 years of age (47). The incidence rate ratios of depression were 2- to 3-fold higher during the 3 years preceding and the 3 years following the diagnosis of epilepsy in the subjects who went on to develop the seizure disorder than in controls; for suicidality, the incidence rate ratio during the 3 years was 4-fold higher before and 1 year after the diagnosis of epilepsy. In a previous population-based study conducted in Sweden, investigators compared the risk of developing unprovoked seizures or epilepsy among patients who had been hospitalized for a psychiatric disorder (n = 1885) with that of a group of controls, matched for gender and year of diagnosis selected randomly from the register of the Stockholm County population (02). The age-adjusted odds ratio for development of unprovoked seizures was 2.5 for people with major depressive disorder, 2.7 for patients with bipolar illness, 2.7 for anxiety disorder, and 2.6 for suicide attempt. Three other population-based studies published between 1990 and 2006 demonstrated that patients with a depressive disorder had a 3- to 7-fold higher risk of developing epilepsy (36; 48; 49). Finally, in a published study of 347 patients with newly diagnosed focal epilepsy, 25% and 26% were found to meet DSM-IV-TR criteria for a mood and anxiety disorder, respectively, whereas 21% of patients endorsed suicidal ideation and 4.7% suicidal attempts (68).

The burden of comorbidity in people with epilepsy is high. Several diseases, including depression, anxiety, dementia, migraine, heart disease, peptic ulcers, and arthritis are up to eight times more common in people with epilepsy than in the general population. Several mechanisms explain how epilepsy and comorbidities are associated, including shared risk factors and bidirectional relations (70).

The use of antidepressant drugs has been traditionally associated with an increased risk of developing seizures and, in fact, seizures are listed as a potential adverse event of all antidepressant drugs. Thus, is the bidirectional relation reported in the studies listed above the expression of an iatrogenic effect of antidepressant drugs used to treat the mood disorder? The available evidence does not appear to support this supposition. Indeed, one study conducted in patients with primary major depressive and obsessive-compulsive disorders compared the incidence of seizures in the course of phase II and III multicenter-randomized placebo-controlled trials between those randomized to placebo or an antidepressant (03). Data for this study encompassed 75,873 patients enrolled in trials submitted to the Food and Drug Administration for regulatory purposes between 1985 and 2004. The trials included antidepressants of the tricyclic, selective serotonin-reuptake inhibitor (SSRI), and serotonin-norepinephrine reuptake inhibitor (SNRI) families as well as mirtazapine and bupropion. The investigators found that subjects randomized to antidepressants were 52% less likely (69% less likely when excluding bupropion immediate release formulation) to develop seizures compared to those randomized to placebo. In addition, patients randomized to placebo were 19 times more likely to experience a seizure compared to the expected incidence in the general population. A higher incidence of seizures was found in patients randomized to clomipramine and bupropion (in its immediate-release formulation) than to placebo. Furthermore, antidepressant drugs of the SSRI and tricyclic families have been found to display antiepileptic effects in several animal models of epilepsy (59) whereas reduction in seizure frequency has been suggested in four open trials with SSRIs in patients with treatment-resistant epilepsy (30; 31; 107; 102) and in one double-blind placebo-controlled trial with imipramine.

Clearly, the data presented above suggest not only that mood disorders may be a risk factor for epilepsy, but they may also increase the likelihood of a treatment-resistant seizure disorder. The existence of common neurobiologic pathogenic mechanisms operant in depressive disorders and epilepsy may explain this phenomenon. These mechanisms include: (1) disturbances of neurotransmitters in the central nervous system, (2) endocrine disturbances, such as hyperactive hypothalamic-pituitary-adrenal axis, resulting in high serum concentrations of cortisol, and (3) inflammatory mechanisms (60; 62).

For example, although disturbances of secretion or receptor sensitivity of serotonin have been identified as pivotal pathogenic mechanisms of completed suicide, major depression, and anxiety disorders, decreased secretion has been identified in several animal models of epilepsy, including the genetically epilepsy-prone rat (54) and the pilocarpine status epilepticus model in the Wistar rat (81) as well as in animal models of epilepsy tested in cats, rabbits, and rhesus monkeys (54). Furthermore, decreased 5HT-1A receptor binding was identified in several PET studies in patients with temporal lobe epilepsy and in patients with primary major depression in the same neuroanatomical structures (amygdala, hippocampi, raphe nuclei, cingulate gyrus, insula) (45).

Glutamate is the “excitatory” neurotransmitter with a key pivotal role in the epileptogenic process. High glutamate concentrations in plasma and CSF have been identified in humans with mood disorders, whereas high concentrations in frontal and occipital cortex have been reported in studies with magnetic resonance spectroscopy (105). In addition, there are data suggesting that NMDA antagonists may exert an antidepressant effect in animal models of depression as well as in humans with treatment-resistant major depressive disorders (117).

In the case of GABA, an inhibitory neurotransmitter, which also plays a pivotal role in the epileptogenic process, low CSF, plasma, and intracortical concentrations have been found in humans with mood disorders (98).

A hyperactive hypothalamic pituitary adrenal axis leading to high secretion of cortisol was identified as one of the neurobiologic markers of major depression almost 40 years ago (19). It is typically tested with the dexamethasone suppression test, which demonstrates a failure to suppress the secretion of cortisol. Likewise, several studies have shown that pretreatment with corticosterone accelerates the kindling process in rats (77). The high cortisol serum concentrations have been associated with structural changes presenting as atrophy in mesial temporal and frontal lobe structures as well as neuropathologic findings, including neuronal and glial density decrements in orbitofrontal and superior frontal lobe structures (24).

With respect to inflammatory disturbances, proinflammatory cytokines, in particular interleukin-1beta (IL-1beta), have been found to play a pathogenic role in patients with mood disorders. In animal models of epilepsy and humans with temporal lobe epilepsy, IL-1beta, has been shown to have pro-convulsant properties, which are blocked by its naturally occurring antagonist (IL-1RA). The pro-convulsant mechanism has been associated to a reduction in glutamate uptake by glial cells or an enhanced release of glutamate from these cells (111; 112).

Prevention

Despite their frequent occurrence, depressive disorders remain under-recognized and under-treated. For example, among 97 patients with epilepsy with depressive episodes severe enough to warrant the use of psychotropic drugs, more than 1 year lapsed before 63% of patients with spontaneous and 54% with iatrogenic episodes were referred for treatment (67). Other investigators identified a current untreated major depressive disorder in 43% of patients with epilepsy, but 38% of patients with lifetime histories of major depressive disorder had never been referred for treatment (114). This problem is not restricted to adults; for example, Ettinger and colleagues found depressive symptomatology in 26% of 44 children with epilepsy who had never been previously evaluated or treated (28). There needs to be a constant effort to increase awareness about the recognition and treatment of these psychiatric comorbidities in patients with epilepsy.

Although rapid identification and treatment of primary depressive disorders is of the essence, anticipation of iatrogenic depressive disorders is also important in patients with epilepsy. Indeed, as stated above, antiepileptic drugs with negative psychotropic properties (eg, barbiturates, topiramate, benzodiazepines, zonisamide, vigabatrin, levetiracetam) can result in depressive symptoms, including major depressive episodes in patients with epilepsy at risk of developing psychiatric disorders (eg, patients with a prior psychiatric history or family history). By the same token, discontinuation of antiepileptic drugs with mood-stabilizing properties in patients with epilepsy with a prior history of depressive disorders may unmask such disorders. Furthermore, the addition of antiepileptic drugs with enzyme-inducing properties may lower the serum concentrations of concomitant antidepressant drugs and limit their efficacy, causing a recurrence of psychiatric symptoms. Finally, clinicians must be on the lookout for postsurgical depressive disorders occurring in 20% to 30% of patients with epilepsy during the first 3 to 6 months following an anterotemporal lobectomy. This risk is increased in patients with a family or personal prior history of depressive disorders. Accordingly, presurgical psychiatric evaluations are of the essence to identify those patients with an increased risk.

Diagnostic workup

Depressive disorders are not difficult to diagnose; furthermore, self-report screening instruments have become available to identify symptoms of depression and major depressive episode--its most severe clinical expression--in patients with epilepsy. These instruments can be given to patients to fill-out in the clinic while waiting to be seen by their doctor, and they are probably the best solution to facilitate their identification in patients with epilepsy in a busy outpatient clinic. These instruments include the Beck Depression Inventory (BDI-II), the Center of Epidemiologic Studies-Depression (CES-D), which have been validated for patients with epilepsy (56), and the Neurological Disorders Depression Inventory in Epilepsy, which is a 6-item instrument that was validated to screen for major depressive episode in patients with epilepsy specifically (40). The latter has the advantage of having been constructed specifically to minimize confounding symptoms that plague other instruments, such as somatic symptoms that may also be the expression of adverse events of antiepileptic drugs or of cognitive problems associated with epilepsy. Patients can fill-out the instrument in less than 3 minutes. A score of higher than 15 is suggestive of a major depressive episode. These instruments are not diagnostic by themselves, and a subsequent, more detailed evaluation is necessary. Once the diagnosis of a mood disorder has been established by psychiatric evaluation, the self-rating screening instruments can be given at every visit to document symptom remission.

As already discussed, comorbid anxiety disorders or symptoms of anxiety are a common occurrence, and their identification and effective treatment is of the essence. The 7-item Patient’s Health Questionnaire Generalized Anxiety Disorder-7 (GAD-7) is an ideal self-rating instrument to screen for generalized anxiety disorder (76). It takes 2 to 3 minutes for patients to complete; a score of higher than 10 is suggestive of a generalized anxiety disorder.

Management

Pharmacologic, psychologic, and neuromodulation therapies have become the treatment modalities available to manage depressive disorders in patients with epilepsy. The most updated recommendations were released in 2021 by The Task Force of the International League Against Epilepsy (ILAE) Commission on Psychiatry, ILAE Executive and the International Bureau for Epilepsy (IBE) (90). These recommendations were based on a systematic review of 11 studies on drug treatments (788 participants, class of evidence III and IV); 13 studies on psychological treatments (998 participants, class of evidence II, III, and IV); and two studies comparing sertraline with cognitive behavioral therapy (155 participants, class of evidence I and IV). The recommendations vary according to the severity of the depression. For mild depression, starting with psychological interventions is the recommended first-line treatment; when medication is required, selective serotonin reuptake inhibitors (SSRIs) are first-choice medications (Level B).

SSRIs remain the first-choice medications (Level B) for moderate to severe depressive episodes; however, switching to venlafaxine appears legitimate (Level C) in patients who are partially or nonresponding to first-line treatment. Antidepressant treatment should be maintained for at least 6 months following remission from a first depressive episode. It should be prolonged to 9 months in patients with a history of previous episodes and should continue even longer in severe depression or in cases of residual symptomatology—until such symptoms have subsided.

The antidepressants of the SSRI and SNRI families have replaced the first generation of tricyclic antidepressants because of their lower toxicity. Unfortunately, to date there are no published double-blind placebo-controlled trials that have tested the efficacy of these two families of antidepressants in patients with epilepsy. One controlled study compared the efficacy of sertraline and cognitive behavior therapy for the treatment of major depressive episodes in patients with epilepsy. Remission of all symptoms was achieved in close to 60% of patients in each arm (41). These findings suggest that the achievement of symptom remission is significantly more likely among patients with epilepsy than in those with primary depression as only 35% to 40% of the latter become asymptomatic after the first trial of an antidepressant medication.

Two consensus statements have been published outlining pharmacological and psychotherapeutic approaches for patients with epilepsy with affective disorders using data from the management of primary mood disorders and from open trials with SSRIs in patients with epilepsy (07; 71). Both documents recommend the use of these antidepressant drugs in patients with epilepsy and emphasize the safety of these drugs when used at therapeutic doses. Four antidepressant drugs should be avoided in patients with epilepsy, however: chlorimipramine, bupropion, amoxapine, and maprotiline; these drugs have been found to be associated with increased risk of seizures.

Before starting pharmacotherapy, it is important to determine if the depressive episodes resulted from an iatrogenic process, which may result from:

	• The introduction of an antiepileptic drug with negative psychotropic properties (eg, barbiturates, topiramate, benzodiazepines, zonisamide, vigabatrin, levetiracetam, and perampanel), particularly in patients with epilepsy at risk of developing psychiatric disorders (eg, patients with a prior psychiatric history or family history).
	• The discontinuation of an antiepileptic drug with mood-stabilizing properties (eg, carbamazepine, oxcarbazepine, valproic acid, lamotrigine) in patients with a personal (or family) history of mood disorder that was in remission or masked by one of these antiepileptic drugs.
	• The addition of an antiepileptic drug with enzyme-inducing properties (carbamazepine, phenytoin, barbiturates) in patients with epilepsy taking an SSRI, which had resulted in remission of the depressive episode. In these patients, these antiepileptic drugs will increase the clearance of the antidepressant, lower its serum concentration, and limit its efficacy.

Another cautionary note is in order: before starting an antidepressant drug, clinicians must rule out a history of a manic or hypomanic episode that may be suggestive of a bipolar disorder as these drugs can potentially trigger a manic or hypomanic episode in the short term, and they may worsen the course of the bipolar disorder in the long-term, resulting in rapid cycling bipolar disease. In such cases, an antiepileptic drug with mood stabilizing and antidepressant properties such as lamotrigine must be considered. Carbamazepine and valproate may be added in case of persistent symptoms. Lithium or atypical antipsychotics with mood stabilizing properties should be considered if these antiepileptic drugs cannot yield a euthymic state. If an antidepressant is required, it should not be started in the absence of a mood-stabilizing drug.

Do antidepressant drugs worsen seizures? For a long time, clinicians have been reluctant to prescribe antidepressant drugs to patients with epilepsy, because of a concern that this type of drugs lowers the seizure threshold. Yet, this appears to be a misunderstanding that needs to be clarified (61). First, reports of seizures in patients taking antidepressant drugs have included patients taking overdoses. Second, based on the evidence suggesting a bidirectional relationship between depression and epilepsy that suggests a higher incidence of seizures in patients with depression, it is important to reconsider the question of whether antidepressants increase the risk of seizures or whether we are identifying the seizure occurrence associated with such increased risk. The study by Alper and colleagues cited above helped to clarify this point as it showed that compared to the expected incidence of seizures of the general population, all depressed patients had a higher incidence, but patients randomized to placebo had a significantly higher incidence of seizures than those treated with the actual antidepressant drug (03).

A review of the literature has found an increased incidence of seizures with the use of four specific antidepressant drugs; these include: maprotiline, amoxapine, clomipramine, and bupropion (82). As stated above, SSRI and SNRIs are expected to be safe in patients with epilepsy when used at therapeutic doses (03). In one study, sertraline was found to definitely worsen seizures in only 1 in 100 patients with refractory epilepsy (67) whereas several open trials have suggested a potential antiepileptic effect of fluoxetine and citalopram (30; 31; 107). In an open trial of SSRIs and SNRIs used for the treatment of depressive or anxiety disorders, Ribot and colleagues found a reduction in seizure frequency of almost 30% among patients with more than one seizure per month (102). This effect was not related to the psychiatric effect of these drugs. However, these data need to be replicated in double-blind placebo-controlled trials.

Blumer has also reported that using tricyclic antidepressants alone and in combination with SSRIs in patients with epilepsy did not lead to any seizure exacerbation (13). Monoamine oxidase-A-inhibitors (MAO-I) are not known to cause seizures in patients without epilepsy. Patients treated with tricyclic antidepressants should be started at low doses with small increments until the desired clinical response is reached to minimize the risk of adverse events. Furthermore, the use of tricyclic antidepressant drugs requires a baseline EKG as well as one when reaching the target dose, as changes have been reported.

Pharmacokinetic interaction between antidepressant drugs and antiepileptic drugs. Most antidepressant drugs are metabolized in the liver, and their metabolism is accelerated in the presence of antiepileptic drugs with enzyme-inducing properties. This pharmacokinetic effect is not observed with the new antiepileptic drugs gabapentin, lamotrigine, tiagabine, levetiracetam, zonisamide, pregabalin, vigabatrin, and perampanel.

Conversely, some of the SSRIs are inhibitors of one or more isoenzymes of the cytochrome P450 (CYP 450) system. These antidepressants include fluoxetine, paroxetine, fluvoxamine, and to a lesser degree, sertraline (93; 37; 42). Escitalopram and citalopram, on the other hand, do not have pharmacokinetic interactions with antiepileptic drugs (82). Sertraline has been shown rarely to increase phenytoin levels, and this is thought to be associated with displacement by tight protein binding, or by inhibition of the CYP 450 system (44).

Choice of antidepressant. The criteria used to choose an antidepressant must be based on the following:

	• Type of depressive episode: retarded versus agitated. In the former, SNRIs may be more effective, given their noradrenergic effect. In the latter, SSRIs should be considered first.
	• Presence of comorbid anxiety disorders and their type. In such cases, the clinician must identify the SSRI or SSRI that can cover the symptoms of both conditions. Failure to treat comorbid anxiety disorders will result in increased risk of recurrence of the depressive disorder or failure to reach symptom remission.
	• Adverse event profile of the antidepressant drug, in particular those drugs with a propensity to cause weight gain.

Dosing of the antidepressant must be the same as in the treatment of primary mood disorders. The aim is to achieve complete symptom remission as persistence of symptoms is associated with an increased risk of recurrence of a major depressive episode. Furthermore, clinicians must adjust the dose in the presence of enzyme-inducing antiepileptic drugs by increasing it by 30%.

Other types of psychiatric treatments. Lithium was the first “mood stabilizing drug” used for the treatment of patients with primary bipolar disorder. Its use has been fraught with several problems, including changes in EEG recordings and pro-convulsant effects at therapeutic serum concentrations in patients without epilepsy (08). Lithium’s neurotoxicity and related increase in seizure risk increases with the concurrent use of neuroleptic drugs, in the presence of EEG abnormalities, and with a history of CNS disorder.

Vagal nerve stimulation is used as adjunctive treatment for epilepsy and has also shown longer-term mood effects (79). A study of 59 patients with epilepsy with depression demonstrated amelioration of the severity of symptoms of depression after 2 years using the Montgomery–Asberg Depression Rating Scale (MADRS) and Beck-Depressions-Inventory (BDI) (108). Vagal nerve stimulation was also found to be beneficial in mood, suicidality, and quality-of-life in 35 patients with drug-resistant epilepsy (73). The impact of other neurostimulation interventions on mood in patients with epilepsy, such as deep brain stimulation or transcranial magnetic stimulation, has not been studied in controlled trials.

Electroconvulsive therapy is not contraindicated in depressed patients with epilepsy (100; 34). It is a well-tolerated treatment and is worth considering in patients with epilepsy with very severe depression that fails to respond to antidepressant drugs. Furthermore, there is no evidence that electroconvulsive therapy increases the risk of epilepsy (09), and in fact, it has been used in the treatment of refractory status epilepticus.

In addition to pharmacological intervention, the value of psychotherapy for the treatment of depression in patients with epilepsy should not be overlooked. Surveys reveal that fear of the next seizure is rated as the greatest concern in patients with epilepsy (35). Counseling and psychotherapy, in particular cognitive behavior therapy, can be useful in helping the patient deal with the stressors and limitations of living with epilepsy (99).

More recently, the randomized, controlled crossover study UPLIFT demonstrated the efficiency of a mindfulness-based cognitive therapy intervention for preventing major depressive disorder episodes in patients with epilepsy (110).

Psychological treatments for adults and children with epilepsy. Evidence-based recommendations by the International League Against Epilepsy Psychology Task Force determined that current evidence supports psychological therapies that target comorbid mental health symptoms, and health-related quality-of-life (HRQOL) should be considered in the comprehensive treatment of individuals with epilepsy. The strongest evidence was identified for the most common mental health problems, including depression, as well as health behaviors, such as adherence. Treatments for these disorders and challenges received STRONG recommendations (85).

References

01: Adams SJ, Velakoulis D, Kaye AH, Corcoran NM, O'Brien TJ. Psychiatric history does not predict seizure outcome following temporal lobectomy for mesial temporal sclerosis. Epilepsia 2012;53:1700-4. PMID 22738237
02: Adelow C, Anderson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology 2012;78:396-401. PMID 22282649
03: Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62(4):345-54. PMID 17223086
04: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. American Psychiatric Association, 2013.
05: Barabas G, Matthews WS. Barbiturate anticonvulsants as a cause of severe depression. Pediatrics 1988;82(2):284-85. PMID 3399308
06: Barclay L. FDA requires warnings about suicidality risk with antiepileptic drugs. Medscape Medical News. Accessed 2008.
07: Barry JJ, Ettinger AB, Friel P, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 2008;13 Suppl 1:S1-29. PMID 18502183
08: Bell AJ, Cole A, Eccleston D, Ferrier IN. Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 1993;162:689-92. PMID 8149125
09: Blackwood DH, Cull RE, Freeman CP, Evans JI, Mawdsley C. A study of the incidence of epilepsy following ECT. J Neurol Neurosurg Psychiatry 1980;43(12):1098-102. PMID 7217955
10: Blanchet P, Frommer GP. Mood change preceding epileptic seizures. J Nerv Ment Dis 1986;174(8):471-6. PMID 3734769
11: Blumer D, Altshuler LL. Affective disorders. In: Engel J, Pedley TA, editors. Epilepsy: a Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott-Raven, 1998:2083-99.
12: Blumer D, Montouris G, Davies K. The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy. Epilepsy Behav 2004;5(6):826-40. PMID 15582829
13: Blumer D, Zielinksi J. Pharmacologic treatment of psychiatric disorders associated with epilepsy. J Epilepsy 1988;1:135-50.
14: Bolling-Ladegaard E, Dreier JW, Kessing LV, Budtz-Jørgensen E, Lolk K, Christensen J. Directionality of the association between epilepsy and depression: a nationwide register-based cohort study. Neurology 2023;100(9):e932-42. PMID 36414426
15: Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987;80(6):909-17. PMID 3684404
16: Caplan R, Siddarth P, Gurbani S, Hanson R, Sankar R, Shields WD. Depression and anxiety disorders in pediatric epilepsy. Epilepsia 2005;46(5):720-30. PMID 15857439
17: Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007;6(8):693-8. PMID 17611160
18: Cleary RA, Thompson PJ, Fox Z, Foong J. Predictors of psychiatric and seizure outcome following temporal lobe epilepsy surgery.Epilepsia 2012;53(10):1705-12. PMID 22881990
19: Coryell W, Young E, Carroll B. Hyperactivity of the hypothalamic–pituitary–adrenal axis and mortality in major depressive disorder. Psychiatry Res 2006;142(1):99-104. PMID 16631257
20: Cramer JA, Blum D, Fanning K, Reed M; Epilepsy Impact Project Group. The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav 2004;5:337-42. PMID 15145303
21: Cramer JA, Blum D, Reed M, Fanning K; Epilepsy Impact Project Group. The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav 2003;4:515-21. PMID 14527494
22: Daly D. Ictal affect. Am J Psychiatry 1958;115(2):97-108. PMID 13559503
23: de Araujo Filho GM, Gomes FL, Mazetto L, et al. Major depressive disorder as a predictor of a worse seizure outcome one year after surgery in patients with temporal lobe epilepsy and mesial temporal sclerosis. Seizure 2012;21(8):619-23. PMID 22824233
24: Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008;213(1-2):93-118. PMID 18704495
25: Edeh J, Toone B. Relationship between interictal psychopathology and the type of epilepsy. Results of a survey in general practice. Br J Psychiatry 1987;151:95-101. PMID 3118998
26: Ettinger A, Reed M, Cramer J; Epilepsy Impact Project Group. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 2004;63(6):1008-14. PMID 15452291
27: Ettinger AB, Carter JA, Rajagopalan K. Patient versus neurologist preferences: a discrete choice experiment for antiepileptic drug therapies. Epilepsy Behav 2018;80:247-53. PMID 29433949
28: Ettinger AB, Weisbrot DM, Nolan EE, et al. Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia 1998;39(6):595-9. PMID 9637601
29: Fazel S, Wolf A, Långström N, Newton CR, Lichtenstein P. Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet 2013;382(9905):1646-54. PMID 23883699
30: Favale E, RubinoV, Mainardi P, Lunardi G, Albano C. The anticonvulsant effect of fluoxetine in humans. Neurology 1995;45(10):1926-7. PMID 7477995
31: Favale E, Audenino D, Cocito L, Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 2003;12(5):316-8. PMID 12810346
32: Ferrari M, Barabas G, Matthews WS. Psychologic and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants. Am J Psychiatry 1983;140(1):112-3. PMID 6847971
33: Fiest KM, Dykeman J, Patten SB, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology 2013;80(6):590-9. PMID 23175727
34: Fink M, Kellner CH, Sackeim HA. Intractable seizures, status epilepticus, and ECT. J ECT 1999;15(4):282-4. PMID 10614038
35: Fisher RS, Vickrey BG, Gibson P, et al. The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions. Epilepsy Res 2000;41(1):39-51. PMID 10924867
36: Forsgren L, Nystrom L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res 1990;6(1):66-81. PMID 2357957
37: Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84(6):583-4. PMID 1792934
38: Gaus V, Kiep H, Holtkamp M, Burkert S, Kendel F. Gender differences in depression, but not in anxiety in people with epilepsy. Seizure 2015;32:37-42. PMID 26552559
39: Gilliam F, Kuzniecky R, Faught E, Black L, Carpenter G, Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 1997;38(2):233-6. PMID 9048677
40: Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006;5(5):399-405. PMID 16632310
41: Gilliam FG, Black KJ, Carter J, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Ann Neurol 2019;86(4):552-60. PMID 31359460
42: Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50(1):10-5. PMID 1855347
43: Hancock JC, Bevilacqua AR. Temporal lobe dysrhythmia and impulsive or suicidal behavior: preliminary report. South Med J 1971;64(10):1189-93. PMID 5097792
44: Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 1997;17(2):107-9. PMID 10950473
45: Hasler G, Bonwetsch R, Giovacchini G, et al. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007;62(11):1258-64. PMID 17588547
46: Hesdorffer DC. Comorbidity between neurological illness and psychiatric disorders. CNS Spectr 2016;21(3):230-8. PMID 26898322
47: Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association.Ann Neurol 2012;72:184-91. PMID 22887468
48: Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000;47(2):246-9. PMID 10665498
49: Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol 2006;59(1):35-41. PMID 16217743
50: Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm. Epilepsia 2009;50(5):978-86. PMID 19496806
51: Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007;75(2-3):192-6. PMID 17628429
52: Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia 1996;37(2):148-61. PMID 8635425
53: Jensen AO, Nielsen GL, Ehrenstein V. Validity of asthma diagnoses in the Danish National Registry of Patients, including an assessment of impact of misclassification on risk estimates in an actual dataset. Clin Epidemiol 2010;2:67-72. PMID 20865105
54: Jobe PC. Affective disorder and epilepsy comorbidity in the genetically epilepsy prone-rat (GEPR). In: Gilliam FG, Kanner AM, Sheline YI, editors. Depression and Brain Dysfunction. London: Taylor & Francis, 2006:121-57.
55: Jones JE, Hermann BP, Barry JJ, Gilliam FG, Kanner AM, Meador KJ. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav 2003;4 Suppl 3:S31-8. PMID 14592638
56: Jones JE, Watson R, Sheth R, et al. Psychiatric comorbidity in children with new onset epilepsy. Dev Med Child Neurol 2007;49(7):493-7. PMID 17593119
57: Josephson CB, Lowerison M, Vallerand I, et al. Association of depression and treated depression with epilepsy and seizure outcomes: a multicohort analysis. JAMA Neurol 2017;74(5):533-9. PMID 28241168
58: Kanner AM. Depression and epilepsy: a new perspective on two closely related disorders. Epilepsy Curr 2006;6(5):141-6. PMID 17260039
59: Kanner AM. Depression and epilepsy: How can we explain their bidirectional relation. Epilepsia 2011;52 Suppl 1:21-7. PMID 21214536
60: Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders. Lancet Neurol 2012;11(12):1093-102. PMID 23021976
61: Kanner AM. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: a review of the evidence. Epilepsy Behav 2016;61:282-6. PMID 27236241
62: Kanner AM. Obstacles in the treatment of common psychiatric comorbidities in patients with epilepsy: What is wrong with this picture? Epilepsy Behav 2019;98(Pt B):291-92. PMID 31126824
63: Kanner AM, Balabanov AJ. Psychiatric outcome of epilepsy surgery. In:Lüders HO, Bongaman W, Najim IM, editors. Textbook of Epilepsy Surgery. 3rd ed, Chapter 133a. London: Informa Healthcare, 2008:1254-62.
64: Kanner AM, Barry JJ, Gilliam F, Hermann B, Meador KJ. Anxiety disorders, subsyndromic depressive episodes, and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy. Epilepsia 2010;51(7):1152-8. PMID 20477847
65: Kanner AM, Barry JJ, Gilliam F, Hermann B, Meador KJ. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events. Epilepsia 2012;53(6):1104-8. PMID 22554067
66: Kanner AM, Byrne R, Chicharro A, Wuu J, Frey M. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 2009;72(9):793-9. PMID 19255406
67: Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe. Epilepsy Behav 2000;1(2):100-5. PMID 12609138
68: Kanner AM, Saporta AS, Kim DH, et al. Mood and anxiety disorders and suicidality in patients with newly diagnosed focal epilepsy: an analysis of a complex comorbidity. Neurology 2023;100(11):e1123-34. PMID 36539302
69: Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology 2004;62(5):708-13. PMID 15007118
70: Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol 2016;15(1):106-15. PMID 26549780
71: Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011;52(11):2133-8. PMID 21955156
72: Ketter TA, Malow BA, Flamini R, White SR, Post RM, Theodore WH. Anticonvulsant withdrawal-emergent psychopathology. Neurology 1994;44(1):55-61. PMID 8290092
73: Kim JS, Kim DY, Jo HJ, et al. Effect of long-term treatment with vagus nerve stimulation on mood and quality of life in Korean patients with drug-resistant epilepsy. J Clin Neurol 2021;17(3):385-92. PMID 34184446
74: Koch-Stoecker S. Psychiatric effects of surgery for temporal lobe epilepsy. In: The Neuropsychiatry of Epilepsy. Trimble M, Schmitz B, editors. Cambridge: Cambridge University Press, 2002:266–82.
75: Koch-Stoecker SC, Bien CG, Schulz R, May TW. Psychiatric lifetime diagnoses are associated with a reduced chance of seizure freedom after temporal lobe surgery. Epilepsia 2017;58(6):983-93. PMID 28378900
76: Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317-25. PMID 17339617
77: Kumar G, Couper A, O'Brien TJ, et al .The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology 2007;32(7):834-42. PMID 17614213
78: Lehrner J, Kalchmayr R, Serles W, et al. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Seizure 1999;8(2):88-92. PMID 10222299
79: Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry 2002;51(4):280-7. PMID 11958778
80: Martin RC, Faught E, Richman J, et al. Psychiatric and neurologic risk factors for incident cases of new-onset epilepsy in older adults: data from U.S. Medicare beneficiaries. Epilepsia 2014;55(7):1120-7. PMID 2490247
81: Mazarati AM, Siddarth P, Baldwin RA, et al. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008;131:2071-83.
82: McConnell H, Duncan D. Treatment of psychiatric comorbidity in epilepsy. In: McConnell H, Snyder P, editors. Psychiatric Comorbidity in Epilepsy. Chapter 10. Washington: Am Psych Press, 1998:245-361.
83: McConnell H, Snyder PJ, Duffy JD. Neuropsychiatric side effects to treatment with Felbamate. J Neuropsych Clin Neurosc 1996;8(3):341-6. PMID 8854308
84: Meador KJ, Stowe ZN, Brown C, et al. Prospective cohort study of depression during pregnancy and the postpartum period in women with epilepsy vs control groups. Neurology 2022;99(15). PMID 35977832
85: Michaelis R, Tang V, Goldstein LH, et al. Psychological treatments for adults and children with epilepsy: evidence-based recommendations by the International League Against Epilepsy Psychology Task Force. Epilepsia 2018;59(7):1282-302. PMID 9917225
86: Moseley BD, Cole D, Iwuora O, Strawn JR, Privitera M. The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Res 2015;110:115-8. PMID 25616463
87: Mula M. The interictal dysphoric disorder of epilepsy: legend or reality? Epilepsy Behav 2016;58:7-10. PMID 26991746
88: Mula M, Jauch R, Cavanna A, et al. Clinical and psychopathological definition of the interictal dysphoric disorder of epilepsy. Epilepsia 2008;49(4):650-6. PMID 18093149
89: Mula M, Jauch R, Cavanna A, et al. Interictal dysphoric disorder and periictal dysphoric symptoms in patients with epilepsy. Epilepsia 2010;51(7):1139-45. PMID 20059526
90: Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia 2022;63(2):316-34. PMID 34866176
91: Mula M, Trimble MR. Pharmacokinetic interactions between antiepileptic and antidepressant drugs. World J Biol Psychiatry 2003;4(1):21-4. PMID 12582973
92: O'Donoghue MF, Goodridge DM, Redhead K, Sander JW, Duncan JS. Assessing the psychosocial consequences of epilepsy: a community-based study. Br J Gen Pract 1999;49(440):211-14. PMID 10343425
93: Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990;51(3):126. PMID 2353956
94: Perrine K, Hermann BP, Meador KJ, et al. The relationship of neuropsychological functioning to quality of life in epilepsy. Arch Neurol 1995;52(10):997-1003. PMID 7575228
95: Petrovski S, Szoeke CE, Jones NC, et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology 2010;75(11):1015-21. PMID 20837970
96: Pintor L, Bailles E, Fernández-Egea E, et al. Psychiatric disorders in temporal lobe epilepsy patients over the first year after surgical treatment. Seizure 2007;16(3):218-25. PMID 17204436
97: Quitkin FM. Depression with atypical features: diagnostic validity, prevalence, and treatment. Prim Care Companion J Clin Psychiatry 2002;4(3):94-9. PMID 15014736
98: Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. GABAergic neurons immunoreactive for calcium binding proteins are reducedin the prefrontal cortex in major depression. Neuropsychopharmacology 2007;32(2):471-82. PMID 17063153
99: Ramaratnam S, Baker GA, Goldstein LH. Psychological treatments for epilepsy. Cochrane Database Syst Rev 2008;(3):CD002029. PMID 18646083
100: Regenold WT, Weintraub D, Taller A. Electroconvulsive therapy for epilepsy and major depression. Am J Geriatr Psychiatry 1998;6(2):180-3. PMID 9581214
101: Ribot R, Kanner AM. Neurobiologic properties of mood disorders may have an impact on epilepsy: should this motivate neurologists to screen for this psychiatric comorbidity in these patients? Epilepsy Behav 2019;98(Pt B):298-301. PMID 31182393
102: Ribot R, Ouyang B, Kanner AM. The impact of antidepressants on seizure frequency and depressive and anxiety disorders of patients with epilepsy: Is it worth investigating? Epilepsy Behav 2017;70(Pt A):5-9. PMID 28407526
103: Ring HA, Reynolds EH. Vigabatrin and behaviour disturbance. Lancet 1990;335(8695):970. PMID 1970038
104: Salpekar JA. Neurologists, start your psychotropics! Epilepsy Behav 2021;114(Pt A):107567. PMID 33234458
105: Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002;159(4):663-5. PMID 11925309
106: Scott AJ, Sharpe L, Hunt C, Gandy M. Anxiety and depressive disorders in people with epilepsy: a meta‐analysis. Epilepsia 2017;58(6):973-82. PMID 28470748
107: Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004;27(3):133-6. PMID 15190237
108: Spindler P, Bohlmann K, Straub HB, Vajkoczy P, Schneider UC. Effects of vagus nerve stimulation on symptoms of depression in patients with difficult-to-treat epilepsy. Seizure 2019;69:77-9. PMID 30986721
109: Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48(12):2336-44. PMID 17662062
110: Thompson NJ, Patel AH, Selwa LM, et al. Expanding the efficacy of Project UPLIFT: Distance delivery of mindfulness-based depression prevention to people with epilepsy. J Consult Clin Psychol 2015;83(2):304-13. PMID 25495361
111: Vezzani A, Conti M, De Luigi A, et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999;19(12):5054-65. PMID 10366638
112: Vezzani A, Rizzi M, Conti M, Samanin R. Modulatory role of neuropeptides in seizures induced in rats by stimulation of glutamate receptors. J Nutr 2000;130(4S Suppl):1046S-8S. PMID 10736379
113: Wang J, Wu X, Lai W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open 2017;7(8):e017173. PMID 28838903
114: Wiegartz P, Seidenberg M, Woodard A, Gidal B, Hermann B. Co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression. Neurology 1999;53(suppl.2):S3-8. PMID 10496228
115: Williams D. The structure of emotions reflected in epileptic experiences. Brain 1956;79(1):29-67. PMID 13342275
116: Wrench JM, Rayner G, Wilson SJ. Profiling the evolution of depression after epilepsy surgery. Epilepsia 2011;52(5):900-8. PMID 21426325
117: Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64. PMID 16894061

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Maria Raquel Lopez MD

Dr. Lopez of the University of Miami, Miller School of Medicine has no relevant financial relationships to disclose.
See Profile
Andres M Kanner MD

Dr. Kanner of the University of Miami, Miller School of Medicine has received honorariums from Neurelis and Angelini Laboratories for advisory board service and lecture fees from Jazz Laboratories.
See Profile

Editor

Jerome Engel Jr MD PhD

Dr. Engel of the David Geffen School of Medicine at the University of California, Los Angeles, has no relevant financial relationships to disclose.
See Profile

Former Authors

Ramses Ribot MD

Patient Profile

Age range of presentation: 2 to 65+ years
Sex preponderance: Female>Male, >1:1
Heredity: Hereditary may be a factor
Population groups selectively affected: None selectively affected
Occupation groups selectively affected: None selectively affected

ICD & OMIM codes

ICD-9: Major depressive episode: 296.2

Dysthymia: 300.4

Generalized anxiety disorder: 300.02

Panic disorder: 300.01, 300.21

Localization-related (focal) (partial) epilepsy and epileptic syndromes with complex partial seizures, without mention of intractable epilepsy: 345.50

Localization-related (focal) (partial) epilepsy and epileptic syndromes with complex partial seizures, with intractable epilepsy: 345.41

Generalized convulsive epilepsy: 345.1

Generalized nonconvulsive epilepsy: 345.0
ICD-10: Severe depressive episode without psychotic symptoms: F32.2

Severe depressive episode with psychotic symptoms: F32.3

Dysthymia: F34.1

Generalized anxiety disorder: F41.1

Panic disorder: F41.0

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus: G40.201

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus: G40.209

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus: G40.211

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus: G40.219

Generalized idiopathic epilepsy and epileptic syndromes: G40.3
OMIM: Major depressive disorder 1: %608520

Anxiety: %607834

Panic disorder 1: %167870

Panic disorder 2: %607853

Panic disorder3: %609985

Epilepsy, idiopathic generalized: %600669

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Depressive disorders in epilepsy

Associated Disorders

Anxiety disorders
GAD
Panic disorders
Phobias

Also Relevant

Depression after stroke
Epilepsy
Sleep and depression

Clinical Categories

Epilepsy & Seizures

Patient Handouts

La depresión en los adultos mayores (Spanish)

Depressive disorders in epilepsy …

Depressive disorders in epilepsy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Clinical manifestations particular to epilepsy

Depressive episodes as an iatrogenic effect

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Depressive disorders in epilepsy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Clinical manifestations particular to epilepsy

Depressive episodes as an iatrogenic effect

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

This is an article preview.
Start a Free Account
to access the full version.